

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) An aggregated composition comprising (a) a sub-fragment of the 159-301 fragment of full length VP22 protein, and (b) an oligonucleotide or polynucleotide.
2. (Original) An aggregated composition according to claim 1, which further comprises a pharmaceutically acceptable excipient.
3. (Original) An aggregated composition according to claim 1, wherein the sub-fragment is a VP22 fragment selected from the group consisting of: fragments comprising amino acid residues of either (a) 194-226 of full length VP22, or (b) 191-220 of full length VP22, or (c) 191-226 of full length VP22.
4. (Currently Amended) An aggregated composition according to ~~any one of the preceding claims~~claim 1, wherein the sub-fragment of VP22 is labelled.
5. (Original) An aggregated composition according to claim 4, wherein the sub-fragment is either VP22 peptide 194-226KRRRR labelled at the C terminal end of VP22, or VP22 peptide 194-226K labelled at the C terminal end of VP22.

6. (Currently Amended) An aggregated composition according to ~~any one of the preceding claims~~ claim 1, wherein the sub-fragment of VP22 is modified by deletion or substitution.

7. (Currently Amended) An aggregated composition according to ~~any one of the preceding claims~~ claim 1, wherein the sub-fragment of VP22 is a fusion protein which also comprises a non-VP22 polypeptide sequence.

8. (Currently Amended) A method of making an aggregated composition according to ~~any one of the preceding claims~~ claim 1 comprising (a) mixing the sub-fragment of VP22 with the oligonucleotide or polynucleotide, and (b) allowing the mixture obtained in step (a) to form aggregates, e.g. aggregates with a particle size of about 0.1 to about 5 microns, e.g. about 1 to about 3 microns, e.g. by incubating the mixture at about room temperature for at least about 10 minutes.

9. (Currently Amended) Use of an aggregated composition according to ~~any one of the preceding claims~~ claim 1 to 7 in the manufacture of a medicament for the purpose of therapy or prophylaxis of disease.

10. (Currently Amended) Use of an aggregated composition according to ~~any one of the preceding claims~~ claim 1 to 7 in the manufacture of a medicament to deliver desired molecules to cells in vivo.

O'HARE ET AL.
U.S. National Phase of PCT/GB2004/003854

11. (Currently Amended) Use of an aggregated composition according to ~~any one of~~ claims ~~1 to 7~~ in to deliver desired molecules to cells in vitro.

12. (Currently Amended) A combined preparation comprising (a) an aggregated composition according to ~~any one of~~ claims ~~1 to 7~~, and (b) a disaggregating agent for administration separately or sequentially for use in therapy to treat disease or for use prophylactically to stimulate an immune response or to deliver desired molecules to cells, e.g. in vivo or in vitro